Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

270
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
270
Hepatic Portal System01:21

Hepatic Portal System

5.8K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.8K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

227
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
227
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

564
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
564
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

307
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
307
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

2.8K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Translational uncoupling of renin synthesis and activity reveals a mechanism of kidney vascular remodeling.

Clinical science (London, England : 1979)·2026
Same author

Point-of-care hrHPV mRNA detection with reverse transcription recombinase polymerase amplification on a portable fluorimeter from provider-collected cervical samples in Maputo, Mozambique.

Infectious agents and cancer·2026
Same author

Mock Samples That Mimic Human Cervicovaginal Samples to Accelerate the Development and Evaluation of Assays for High-Risk HPV for Cervical Cancer Screening.

Journal of medical virology·2026
Same author

Patterns and Trends of Colorectal Cancer in the United Arab Emirates: A Retrospective Cohort Study, 2012-2021.

The Gulf journal of oncology·2026
Same author

Krüppel-like factor 2 regulates renin expression in mature juxtaglomerular cells.

American journal of physiology. Renal physiology·2026
Same author

Health systems science education for undergraduate medical students: a 3-year longitudinal curriculum preparing students to drive real-world health system improvement.

BMC medical education·2026

Related Experiment Video

Updated: Jan 29, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.9K

New Treatments for Hepatitis C.

Samuel B Ho1, Ariel Ma1, Jason P Smith1

  • 1is the section chief and is the infectious diseases pharmacist, both in the Division of Gastroenterology at the VA San Diego Healthcare System. is a pharmacist at the VA Greater Los Angeles Healthcare System. Dr. Ho is also professor of medicine at the University of California, San Diego, all in California.

Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS
|February 16, 2019
PubMed
Summary

New direct-acting antiviral therapies are improving sustained virologic response rates. Additional treatment options are currently under development for future use.

More Related Videos

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.3K
Murine Bioluminescent Hepatic Tumour Model
05:23

Murine Bioluminescent Hepatic Tumour Model

Published on: July 17, 2010

17.8K

Related Experiment Videos

Last Updated: Jan 29, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.9K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.3K
Murine Bioluminescent Hepatic Tumour Model
05:23

Murine Bioluminescent Hepatic Tumour Model

Published on: July 17, 2010

17.8K

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Direct-acting antiviral (DAA) therapies have revolutionized the treatment of viral infections.
  • Sustained virologic response (SVR) rates have significantly improved with current DAA regimens.
  • Ongoing research aims to expand treatment options for viral infections.

Purpose of the Study:

  • To review the current landscape of direct-acting antiviral therapies.
  • To highlight advancements in achieving sustained virologic response.
  • To discuss emerging treatment options in the pipeline.

Main Methods:

  • Literature review of recent clinical trials and studies.
  • Analysis of efficacy data for approved and investigational DAAs.
  • Synthesis of information on treatment outcomes and future therapeutic strategies.

Main Results:

  • Current direct-acting antiviral therapies demonstrate high efficacy in achieving sustained virologic response.
  • Several novel treatment options are in late-stage development.
  • The pipeline includes therapies with improved resistance profiles and broader applicability.

Conclusions:

  • Direct-acting antiviral therapies represent a major advancement in managing viral infections.
  • The continuous development of new treatment options promises further improvements in patient outcomes.
  • The future of viral infection treatment is optimistic with ongoing therapeutic innovation.